Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain

Journal of Pain and Symptom Management

Volumn 18, Issue 2, 1999, Pages 120-125

  Gagnon, Bruno ^a   Bruera, Eduardo ^a  

^a GREY NUNS COMMUNITY HOSPITAL   (Canada)

Author keywords

Equianalgesic dose; Methadone; Morphine; Neuropathic pain; Non neuropathic pain

Indexed keywords

HYDROMORPHONE; METHADONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; MALE; NEUROPATHY; ORAL DRUG ADMINISTRATION; PAIN; RATING SCALE; RECTAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANALGESICS, OPIOID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; MORPHINE; NEURALGIA; PAIN;

EID: 0032861870     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(99)00049-4     Document Type: Article

References (21)

1. Bruera E., Schoeller T., Fainsinger R.L., Kastelan C. Palliative care rounds. custom-made suppositories of methadone for severe cancer pain J Pain Symptom Manage. 7:1992;372-374.
2. Fainsinger R., Schoeller T., Bruera E. Methadone in the management of cancer pain. a review Pain. 52:1993;137-147.
3. Bruera E., Pereira J., Watanabe S., Belzile M., Kuehn N., Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Cancer. 78:1996;852-857.
4. Cancer pain: a monograph on the management of cancer pain. Health & Welfare Canada: Minister of Supply and Services Canada, Ottawa H42-2/5 1984E.
5. Foley K. The treatment of cancer pain. N Engl J Med. 313:1985;84-95.
6. Patt R.B., Szalados J.E., Wu C.Ll. Pharmacotherapeutic guidelines. Pratt R.B. Cancer pain. 1993;565-575 Lippincott, Philadelphia.
7. Cherny N.I., Foley K.M. Non-opioid and opioid analgesic pharmacotherapy of cancer pain. Hematol Oncol Clin North Am. 10:1996;79-101.
8. Lawlor P., Ripamonti C., Turner K.et al. Dose ratio between morphine and methadone in patients with cancer pain. a retrospective study Cancer. 82:1998;1167-1173.
9. Mao J., Price D.D., Mayer D.J. Mechanisms of hyperalgesia and morphine tolerance. a current view of their possible interactions Pain. 62:1995;259-274.
10. Bruera E., Kuehn N., Miller M.J., Selmser P., Macmillan K. The Edmonton symptom assessment system (ESAS). a simple method for the assessment of palliative care patients J Palliat Care. 7:1991;6-9.
11. Egbert B., Andersen S., Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-asparate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett. 187:1995;165-168.
12. Portenoy R.K., Foley K.M. Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain. new hypotheses derived from studies of opioid infusions Pain. 43:1990;273-286.
13. Levy M.H. Pharmacologic treatment of cancer pain. N Engl J Med. 335:1996;1124-1132.
14. Bruera E., Macmillan K., Hanson J., MacDonald R.N. The Edmonton staging system for cancer pain. preliminary report Pain. 37:1989;203-209.
15. Foley K. Pain assessment and cancer pain syndromes. Doyle D., Hanks G.W.C., MacDonald N. Oxford textbook of palliative medicine, volume 2. 1998;310-331 Oxford University Press, Oxford.
16. Pratt R.B. Classification of cancer pain and cancer pain syndromes. Pratt R.B. Cancer pain, volume 1. 1993;3-22 Lippincott, Philadelphia.
17. Bruera E., Schoeller T., Wenk R.et al. A prospective multi-center assessment of the Edmonton Staging System for cancer pain. J Pain Symptom Manage. 10:1995;348-355.
18. Sjogren P., Jonsson T., Jensen N.-H.et al. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain. 55:1993;93-97.
19. Clarke J.L., Kalen G.E. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. J Pain Symptom Manage. 10:1995;310-314.
20. Bartlett S.E., Dodd P.R., Smith M.T. Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites. Pharmacol Toxicol. 75:1994;73-81.
21. Pasternak G.W., Kolesnikov Y.A., Babey A.M. Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance. Neuropsychopharmacology. 13:1995;309-313.